ES2133503T3 - Dosificacion inmunologica de un antigeno o un hapteno. - Google Patents

Dosificacion inmunologica de un antigeno o un hapteno.

Info

Publication number
ES2133503T3
ES2133503T3 ES94400166T ES94400166T ES2133503T3 ES 2133503 T3 ES2133503 T3 ES 2133503T3 ES 94400166 T ES94400166 T ES 94400166T ES 94400166 T ES94400166 T ES 94400166T ES 2133503 T3 ES2133503 T3 ES 2133503T3
Authority
ES
Spain
Prior art keywords
antigen
hapten
antibodies
epitope
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94400166T
Other languages
English (en)
Inventor
Philippe Pradelles
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Commissariat a lEnergie Atomique et aux Energies Alternatives CEA
Original Assignee
Commissariat a lEnergie Atomique CEA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Commissariat a lEnergie Atomique CEA filed Critical Commissariat a lEnergie Atomique CEA
Application granted granted Critical
Publication of ES2133503T3 publication Critical patent/ES2133503T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54306—Solid-phase reaction mechanisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54353—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals with ligand attached to the carrier via a chemical coupling agent
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/815—Test for named compound or class of compounds
    • Y10S436/817—Steroids or hormones
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/822—Identified hapten

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

LA INVENCION SE REFIERE A UN PROCEDIMIENTO DE DOSIFICACION INMUNOMETRICA DE UN ANTIGENO O DE UN HAPTENO. CONFORME AL PROCEDIMIENTO, SE PONE EN CONTACTO (FIGURA 1A) EL ANTIGENO O EL HAPTENO (3) A DOSIFICAR CON ANTICUERPOS (2) FIJOS SOBRE UNA FASE SOLIDA, PARA ENLAZAR INMUNOLOGICAMENTE EL ANTIGENO O EL HAPTENO CON EL ANTICUERPO. A CONTINUACION SE REALIZA (FIGURA 1B) UN TRATAMIENTO DE INMOVILIZACION DEL ANTIGENO O DEL HAPTENO (3) MEDIANTE ENLACE COVALENTE (4) SOBRE LA FASE SOLIDA (1), LIBERANDO SU EPITOPE (FIGURA 1C); DESPUES SE LE PONE EN CONTACTO (FIGURA 1D) CON ANTICUERPOS MARCADOS (5) Y SE DETERMINA (FIGURA 1E) LA CANTIDAD DE ANTICUERPOS MARCADOS FIJOS, PARA DEDUCIR DE ELLO LA CONCENTRACION DE ANTIGENO O HAPTENO DE PARTIDA. EN VIRTUD DE ESTA ETAPA DE INMOVILIZACION Y DE LIBERACION DEL EPITOPE, SE OBTIENE UNA SENSIBILIDAD ELEVADA UTILIZANDO SOLAMENTE UN ANTICUERPO.
ES94400166T 1993-01-28 1994-01-26 Dosificacion inmunologica de un antigeno o un hapteno. Expired - Lifetime ES2133503T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9300869A FR2700855B1 (fr) 1993-01-28 1993-01-28 Dosage immunométrique d'un antigène ou d'un haptène.

Publications (1)

Publication Number Publication Date
ES2133503T3 true ES2133503T3 (es) 1999-09-16

Family

ID=9443449

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94400166T Expired - Lifetime ES2133503T3 (es) 1993-01-28 1994-01-26 Dosificacion inmunologica de un antigeno o un hapteno.

Country Status (7)

Country Link
US (1) US5476770A (es)
EP (1) EP0609144B1 (es)
JP (1) JP3310090B2 (es)
CA (1) CA2113383C (es)
DE (1) DE69418501T2 (es)
ES (1) ES2133503T3 (es)
FR (1) FR2700855B1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688506A (en) * 1994-01-27 1997-11-18 Aphton Corp. Immunogens against gonadotropin releasing hormone
US5619955A (en) * 1995-06-29 1997-04-15 Stone Products, Inc. Harness gripping aid for tandem riders
FI100276B (fi) * 1996-02-06 1997-10-31 Orion Yhtymae Oy Menetelmä analyyttien ei-kilpailevaa määritystä varten
FR2799839A1 (fr) * 2000-02-02 2001-04-20 Commissariat Energie Atomique Procede pour determiner la capacite antioxydante de composes chimiques et procedes de dosage et d'immobilisation utilisables pour cette determination
US6769347B1 (en) 2002-11-26 2004-08-03 Recon/Optical, Inc. Dual elevation weapon station and method of use
EP1594962B1 (en) 2003-01-31 2014-08-27 Promega Corporation Covalent tethering of functional groups to proteins
US7429472B2 (en) 2003-01-31 2008-09-30 Promega Corporation Method of immobilizing a protein or molecule via a mutant dehalogenase that is bound to an immobilized dehalogenase substrate and linked directly or indirectly to the protein or molecule
FR2853965B1 (fr) * 2003-04-15 2006-09-15 Commissariat Energie Atomique Procede de criblage de conditions operatoires d'une reaction chimique de couplage et trousses pour la mise en oeuvre de ce procede
US20050227351A1 (en) * 2004-04-08 2005-10-13 Awdalla Essam T Methods and compound protein molecules used for inducing cytotoxic cell-mediated immune response in a mammal against a pathogenic cell
US20070087400A1 (en) * 2004-07-30 2007-04-19 Aldis Darzins Covalent tethering of functional groups to proteins and substrates therefor
US7425436B2 (en) 2004-07-30 2008-09-16 Promega Corporation Covalent tethering of functional groups to proteins and substrates therefor
EP1989548A2 (en) * 2006-02-08 2008-11-12 Promega Corporation Compositions and methods for capturing and analyzing cross-linked biomolecules
EP2374875B1 (en) 2006-10-30 2015-09-02 Promega Corporation Mutant hydrolase proteins with enhanced kinetics and funcitional expression
DE102007045099A1 (de) * 2007-09-20 2008-10-30 Dade Behring Marburg Gmbh Verfahren zur Bestimmung eines Analyten mittels Ultraschall

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) * 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4459359A (en) * 1981-11-19 1984-07-10 New York Blood Center, Inc. Sensitive immunoassays of antigens or antibodies sequestered within immune complexes
US4703001A (en) * 1985-10-23 1987-10-27 Synbiotics, Corporation Immunoassay for the detection of serum analytes using pH dependent chastropic acids
US4794090A (en) * 1986-09-26 1988-12-27 W. R. Grace & Co.-Conn. Immobilization support for biologicals
US5236830A (en) * 1988-11-10 1993-08-17 Eiji Ishikawa Method of assay for antigen
DK100490D0 (da) * 1990-04-24 1990-04-24 Novo Nordisk As Overflademodifikation
EP0467078B1 (en) * 1990-07-18 1996-05-08 Abbott Laboratories An analyte-subtitute reagent for use in specific binding assay methods, devices and kits

Also Published As

Publication number Publication date
DE69418501D1 (de) 1999-06-24
EP0609144B1 (fr) 1999-05-19
JPH06273416A (ja) 1994-09-30
CA2113383A1 (en) 1994-07-29
FR2700855A1 (fr) 1994-07-29
US5476770A (en) 1995-12-19
CA2113383C (en) 2007-04-24
EP0609144A1 (fr) 1994-08-03
JP3310090B2 (ja) 2002-07-29
DE69418501T2 (de) 1999-12-16
FR2700855B1 (fr) 1995-03-03

Similar Documents

Publication Publication Date Title
ES2133503T3 (es) Dosificacion inmunologica de un antigeno o un hapteno.
AR007249A1 (es) Preparacion concentrada de anticuerpos
ES2110236T3 (es) Dispositivo mejorado destinado para dosificados inmunologicos quimioluminiscentes automaticos.
SE8803486D0 (sv) Dosage form for treating cardiovascular diseases
MY104946A (en) Antigen antibody conjugate.
DE3750339D1 (de) HTLV-III umhüllende Peptiden.
DK25084A (da) Human-human hybridoma mod neoplasmer
ES2110230T3 (es) Ensayo de rapamicina.
KR850000248A (ko) 이뮤노톡신 결합체의 제조방법
DE68917126D1 (de) T-zellen-epitope als träger für einen konjugierten impfstoff.
AU570405B2 (en) Conjugates of muramyl-peptides and haptenes
SE397139B (sv) Sett att pavisa karoninoembryonalt antigen i blod medelst radioimmunoanalysteknik
NO881151L (no) Syntetisk hiv-1-antigen.
DK0470184T3 (da) Specifikke antistoffer for det CD4-bindende domæne i HIV
DK0474691T3 (da) Monoklonale antistoffer til induktion af tolerance
DE3379400D1 (en) Acetaminophen analogs, antigens, and antibodies
DE2964386D1 (en) Therapeutic means for immune complex diseases
NO173511C (no) Fremgangsmaate for fremstilling av et humant monoklonalt antistoff som er i stand til aa gjenkjenne samtidig og binde til hvert O-antigen av to serotyper av Pseudomonas aeruginosa
ES2015349A6 (es) Metodo para producir anticuerpos inmunologicamente reactivos con angiogenina.
KR900011477A (ko) 항-트립타아제 항체 및 이것을 사용한 후천성 면역결핍증 치료용 조성물
JPS55141452A (en) Synthetic polypeptide
ES2061664T3 (es) Anticuerpos monoclonales que reconocen a alfa-hanp y correspondientes hibridomas, su preparacion y uso.
ES2082962T3 (es) Medicamentos y metodos de tratamiento del sindrome de inmunodeficiencia adquirida (sida) y del complejo relacionado con el sida (arc) que utilizan anticuerpos anti-carbohidrato.
DE3273844D1 (en) Procedure for immunological determinations using two antibodies, the second antibody being purified by affinity chromatography, and supports therefor
ES2090331T3 (es) Ctaa 28a32, antigeno reconocido por mca 28a32.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 609144

Country of ref document: ES